Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Telesis Bio, Inc. - Common Stock (NQ: TBIO )

3.230 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Telesis Bio, Inc. - Common Stock

< Previous 1 2 Next >
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports First Quarter 2024 Financial Results
From Telesis Bio
Via GlobeNewswire
Telesis Bio Announces Reverse Stock Split
From Telesis Bio
Via GlobeNewswire
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
From Telesis Bio
Via GlobeNewswire
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
Via AB Newswire
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expense 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports Third Quarter 2023 Financial Results
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
From Telesis Bio
Via GlobeNewswire
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology Workstation 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Appoints William J. Kullback Chief Financial Officer
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports Second Quarter 2023 Financial Results
-- Total revenue of $8.7M in 2QFY23 - increased by 53% year over year 
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Present at Jefferies Healthcare Conference 2023
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock
From Telesis Bio
Via GlobeNewswire
Telesis Bio Secures Financing of $28.0 Million
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit
New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit
New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation 
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports First Quarter 2023 Financial Results
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
From Telesis Bio
Via GlobeNewswire
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation 
From Telesis Bio
Via GlobeNewswire
Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Present at Festival of Biologics Conference
Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” 
From Telesis Bio
Via GlobeNewswire
Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
From Telesis Bio
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS